Dyadic International (DYAI) Non-Current Assets (2017 - 2026)
Dyadic International (DYAI) posted Non-Current Assets of $109677.0 for Q1 2026, up 123.5% sequentially from $49072.0 in Q4 2025, and up 22.32% YoY from $89666.0 in Q1 2025.
Dyadic International (DYAI) Non-Current Assets (2017 - 2026) Analysis & Trends
Dyadic International has reported Non-Current Assets for 10 years, with the latest figure at $109677.0 in Q1 2026.
- Quarterly Non-Current Assets rose 22.32% year-over-year to $109677.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 million (up 133.77% YoY) and the FY2025 annual result came in at $49072.0, down 52.17% from the prior year.
- Non-Current Assets grew to $109677.0 in Q1 2026 per DYAI's latest filing, from $49072.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $2.3 billion in Q1 2022 and troughed at $5822.0 in Q2 2023.
- A 5-year average of $134.8 million and a median of $127771.0 in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets soared 786853.52% in 2022, then slumped 100.0% in 2023.
- Over 5 years, Non-Current Assets stood at $290754.0 in 2022, then sank by 47.76% to $151901.0 in 2023, then slumped by 32.45% to $102607.0 in 2024, then sank by 52.17% to $49072.0 in 2025, then soared by 123.5% to $109677.0 in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $109677.0, $49072.0, and $127495.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Dyadic International | 19.98 Mn | 19.98 Mn | - | 109,677.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 109,677.00 |
| Dec 31, 2025 | 49,072.00 |
| Sep 30, 2025 | 127,495.00 |
| Jun 30, 2025 | 731,307.00 |
| Mar 31, 2025 | 89,666.00 |
| Dec 31, 2024 | 102,607.00 |
| Sep 30, 2024 | 115,242.00 |
| Jun 30, 2024 | 127,771.00 |
| Mar 31, 2024 | 139,954.00 |
| Dec 31, 2023 | 151,901.00 |
| Sep 30, 2023 | 167,698.00 |
| Jun 30, 2023 | 5,822.00 |
| Mar 31, 2023 | 6,065.00 |
| Dec 31, 2022 | 290,754.00 |
| Sep 30, 2022 | 290,712.00 |
| Jun 30, 2022 | 290,733.00 |
| Mar 31, 2022 | 2.29 Bn |
| Dec 31, 2021 | 290,826.00 |
| Sep 30, 2021 | 290,852.00 |
| Jun 30, 2021 | 290,881.00 |